CVS's Shift On Humira Biosimilars May Not Be What The Doctor

CVS Caremark changed its formulary to favor Hyrimoz. But this may not be what policymakers had in mind ten years ago when they first thought about biosimilar competition.

Related Keywords

Cuba , Cuban , , Mark Cuban Cost Plus Drug Company , Cigna , Quallent Pharmaceuticals , Novartis , Endpoints News , Formulary Watchsays , Express Scripts , Mark Cuban , Cost Plus Drug Company , Cvs Caremark , Cvs Health , Humira , Hyrimoz , Biosimilars , Yformulary , Vertical Integration ,